Feasibility of Antifibrinolytic Treatment in Hemophilia: Preliminary Study

We present a randomized clinical trial of prophylactic antifibrinolytic treatment carried out for a period of 15 days in a summer camp (Rosamarina-Puglia-Italy) on 22 hemophiliacs: 11 were treated with A.M.C.H.A and 11 without. Both groups were homogeneous regarding age of patients, type and severity of the disease. The aims of study were: 1- Prophylaxis of the spontaneous recurrent hemarthrosis 2- Possible saving of hemoderivate after traumatic hemarthrosis 3- Possible acceleration of the recovery. The first group was treated with 500 mg of A.M.C.H.A per person given by mouth three times a day. The number of hemarthrosis were 26 in the prophylactic group and 20 in the control. The total amount of units of factor VIII or IX were 7600 in the treated group, while they were 13200 in the control. The average amount of plasma factor units per person in the treated group were 690, while they were 1200 in the control one. Finally in all but one of the treated patients we observed that only one infusion was sufficient to recover the hemorrhagic episode. Our results are encouraging and can stimulate a double-blind multicenter clinical trial on the prophylactic treatment in hemophilia.